| Withdrawn | Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer NCT06557278 | Mirror Biologics, Inc. | Phase 2 |
| Not Yet Recruiting | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer NCT07318389 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) NCT07416552 | Hoffmann-La Roche | Phase 1 |
| Not Yet Recruiting | JS212 Combination Therapies in Metastatic Colorectal Cancer NCT07503756 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases NCT07277322 | Dan Feng | Phase 1 / Phase 2 |
| Not Yet Recruiting | Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Li NCT07359456 | UNICANCER | Phase 2 |
| Recruiting | Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients NCT07314294 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 2 |
| Suspended | Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer U NCT05375708 | UMC Utrecht | Phase 2 |
| Recruiting | A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With NCT07255664 | Curacell Holding AB | Phase 1 / Phase 2 |
| Recruiting | A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. NCT07263178 | Boryung Pharmaceutical Co., Ltd | — |
| Recruiting | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Profic NCT06856837 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Withdrawn | Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer NCT06501989 | Inova Health Care Services | Phase 2 |
| Not Yet Recruiting | BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients NCT07071844 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Withdrawn | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Me NCT06603818 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastati NCT06959550 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another I NCT07079631 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | Trial of ProAgio in Advanced/Metastatic Colorectal Cancer NCT06867822 | University of Alabama at Birmingham | Phase 1 |
| Not Yet Recruiting | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of U NCT07025239 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Withdrawn | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer NCT05690035 | Sun Yat-sen University | Phase 2 |
| Recruiting | Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovi NCT06808685 | Libbs Farmacêutica LTDA | — |
| Recruiting | Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSE NCT06907342 | St. Olavs Hospital | Phase 2 |
| Recruiting | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer NCT06675513 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Recruiting | Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. NCT03401294 | University of Saskatchewan | Phase 2 |
| Recruiting | Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third NCT06980532 | Liu Huang | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combin NCT06820463 | AbbVie | Phase 2 |
| Not Yet Recruiting | Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer NCT06858969 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Me NCT06245356 | UNICANCER | Phase 2 |
| Recruiting | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer NCT06792695 | AstraZeneca | Phase 2 |
| Recruiting | A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and C NCT06979908 | The First Hospital of Jilin University | Phase 2 |
| Recruiting | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer NCT06824064 | Riboscience, LLC. | Phase 2 |
| Recruiting | A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Tr NCT06614192 | AbbVie | Phase 3 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer NCT06653010 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Recruiting | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients NCT06493760 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Recruiting | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harbor NCT06412198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With M NCT06551207 | Liu Huang | N/A |
| Not Yet Recruiting | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer NCT06341309 | West China Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy NCT06513221 | Fudan University | Phase 2 |
| Recruiting | Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAG NCT06202183 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal C NCT06425133 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Recruiting | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve NCT06252649 | Amgen | Phase 3 |
| Recruiting | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer NCT06341296 | West China Hospital | Phase 2 |
| Recruiting | FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer NCT06563986 | UMC Utrecht | Phase 2 |
| Not Yet Recruiting | Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab NCT06415851 | Zhangfa Song | Phase 2 |
| Recruiting | Combination Therapy for BRAF-V600E Metastatic CRCm NCT06411600 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Not Yet Recruiting | A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer NCT06363552 | Tianshu Liu | Phase 2 |
| Recruiting | Sacituzumab Govitecan in Metastatic Colorectal Cancer NCT06243393 | University Hospital Heidelberg | Phase 2 / Phase 3 |
| Unknown | Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic NCT06347198 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Not Yet Recruiting | FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype NCT06191120 | UMC Utrecht | N/A |
| Recruiting | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Ag NCT06149481 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus NCT06225622 | Shanghai Zhongshan Hospital | Phase 1 |
| Recruiting | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC NCT06485713 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Recruiting | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081 | Beijing Hospital | Phase 2 |
| Not Yet Recruiting | A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLE NCT06195111 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Meta NCT06137170 | Bayer | — |
| Active Not Recruiting | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and NCT06106308 | Cardiff Oncology | Phase 2 |
| Recruiting | Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liv NCT06225843 | Alethia Biotherapeutics | Phase 2 |
| Unknown | Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases NCT06231017 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encora NCT05985954 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy NCT06290856 | Oslo University Hospital | — |
| Recruiting | ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases NCT05787197 | GERCOR - Multidisciplinary Oncology Cooperative Group | — |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Not Yet Recruiting | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capec NCT06195670 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With R NCT06039202 | Holy Stone Healthcare Co., Ltd | Phase 2 |
| Recruiting | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unrese NCT06218810 | Fudan University | Phase 2 |
| Recruiting | Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advan NCT06776757 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Phase 1 / Phase 2 |
| Recruiting | MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases NCT06208397 | Shengjing Hospital | — |
| Recruiting | ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer NCT06543836 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Le NCT05959356 | Sun Yat-sen University | Phase 2 |
| Unknown | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. NCT06060704 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent NCT06075849 | Panolos Bioscience | Phase 1 |
| Recruiting | Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer NCT06118762 | The First Affiliated Hospital of Nanchang University | Phase 4 |
| Recruiting | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer NCT05854498 | University of Wisconsin, Madison | Phase 2 |
| Active Not Recruiting | A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients NCT05487248 | Jules Bordet Institute | N/A |
| Unknown | Fruquintinib in the Cross-line Treatment of Refractory mCRC NCT06099314 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Withdrawn | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction T NCT05412706 | Ospedale Policlinico San Martino | Phase 2 |
| Recruiting | Sulfasalazine in Patients With Metastatic Colorectal Cancer NCT06134388 | Tanta University | Phase 3 |
| Completed | An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients W NCT06029010 | Bayer | — |
| Recruiting | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy NCT05962502 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer NCT05843188 | University Health Network, Toronto | Phase 2 |
| Unknown | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab NCT06118047 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer NCT05639413 | UNICANCER | N/A |
| Recruiting | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC NCT05970705 | Fudan University | Phase 2 |
| Unknown | The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Ca NCT05555901 | Fudan University | Phase 2 |
| Recruiting | Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colo NCT05299840 | Oncomedics | N/A |
| Recruiting | Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer NCT05840263 | University of Colorado, Denver | — |
| Recruiting | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorec NCT05462613 | Centre Hospitalier Universitaire de Besancon | Phase 2 / Phase 3 |
| Recruiting | Second-line Treatment of Metastatic Colorectal Cancer NCT06242067 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Can NCT05462236 | AUM Biosciences Pte Ltd | Phase 2 |
| Completed | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Lin NCT05593328 | Cardiff Oncology | Phase 2 |
| Unknown | Nitazoxanide in Patients With Metastatic Colorectal Cancer NCT06049901 | Tanta University | Phase 3 |
| Recruiting | On-treatment Biomarkers in Metastatic Colorectal Cancer for Life NCT05755672 | Region Skane | — |
| Not Yet Recruiting | SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC NCT05747716 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Terminated | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer NCT05743036 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 |
| Unknown | Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal NCT05721872 | Nazarbayev University | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatmen NCT05775900 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Terminated | Electroporation and Immunotherapy in Metastatic Colorectal Cancer NCT05609656 | Ismail Gögenur | Phase 2 |
| Recruiting | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody T NCT05694936 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Unknown | Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-L NCT05659290 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Unknown | Effect of Silymarin in Metastatic Colorectal Cancer Patients NCT05631041 | Tanta University | Phase 3 |
| Not Yet Recruiting | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic C NCT05652894 | Taizhou Hanzhong biomedical co. LTD | Phase 3 |
| Completed | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer NCT05513742 | Compass Therapeutics | Phase 2 |
| Recruiting | The Impact of Radiotherapy on Oligometastatic Cancer NCT05933876 | Institut Investigacio Sanitaria Pere Virgili | — |
| Unknown | The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-muta NCT05634590 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer NCT05608044 | Agenus Inc. | Phase 2 |
| Active Not Recruiting | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Ti NCT05201352 | Centre Georges Francois Leclerc | Phase 1 / Phase 2 |
| Recruiting | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients NCT06202001 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer NCT05725200 | Oslo University Hospital | Phase 2 |
| Terminated | Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) NCT05281276 | Taipei Medical University Shuang Ho Hospital | Phase 1 |
| Not Yet Recruiting | 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma NCT05531045 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer NCT05447715 | Weijian Guo | Phase 2 |
| Recruiting | TARGETed Therapy Drug MONITOring in DIGestive Oncology NCT05443087 | UNICANCER | N/A |
| Completed | An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recomm NCT05551039 | Bayer | — |
| Completed | Safety of Effivia®, a Bevacizumab Biosimilar NCT06313268 | Laboratorios Liomont | — |
| Unknown | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer NCT05522738 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients NCT06403709 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy NCT05291156 | University of Campania Luigi Vanvitelli | Phase 2 |
| Active Not Recruiting | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in Peo NCT05217446 | Pfizer | Phase 2 |
| Terminated | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Adva NCT05330429 | Gilead Sciences | Phase 2 |
| Unknown | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). NCT05201612 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Phase 2 |
| Unknown | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC NCT05438108 | Huazhong University of Science and Technology | Phase 2 |
| Active Not Recruiting | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 | Akeso | Phase 2 |
| Unknown | Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention NCT05635630 | Fudan University | N/A |
| Recruiting | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC NCT05310643 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Withdrawn | Medical Food for the Dietary Management of Metastatic Colorectal Cancer NCT05183295 | Faeth Therapeutics | N/A |
| Terminated | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiraci NCT05223673 | Institut de Recherches Internationales Servier | Phase 3 |
| Unknown | Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer NCT05016869 | Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation NCT05127759 | Shanghai Henlius Biotech | Phase 2 |
| Unknown | Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwa NCT06495463 | Chang Gung Memorial Hospital | N/A |
| Terminated | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer NCT04786600 | University of Florida | Phase 2 |
| Unknown | Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC NCT05004831 | Sun Yat-sen University | Phase 2 |
| Recruiting | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC NCT05229003 | Fudan University | Phase 2 |
| Completed | Fruquintinib DDI Study With P-gp and BCRP Substrates NCT05368805 | Hutchmed | Phase 1 |
| Active Not Recruiting | Pressure-enabled Delivery in Radioembolization (TriNav Study) NCT05128032 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | A Study of ES104 in Patients With Metastatic Colorectal Cancer NCT05167448 | Elpiscience (Suzhou) Biopharma, Ltd. | Phase 1 / Phase 2 |
| Unknown | A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer NCT05130021 | Maxinovel Pty., Ltd. | Phase 2 |
| Terminated | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM NCT03678428 | Sun Yat-sen University | Phase 3 |
| Recruiting | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatme NCT05007132 | Dominik Paul Modest | Phase 2 |
| Completed | A Screening Study Targeting Tumor-specific Antigens NCT05158621 | Gritstone bio, Inc. | — |
| Terminated | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment NCT04952753 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC NCT04926376 | ABK Biomedical | N/A |
| Unknown | Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Ch NCT05103020 | Yonsei University | Phase 2 |
| Recruiting | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic NCT04929223 | Hoffmann-La Roche | Phase 1 |
| Unknown | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer NCT05266820 | Fujian Cancer Hospital | Phase 2 |
| Completed | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies NCT05039177 | Erasca, Inc. | Phase 1 / Phase 2 |
| Completed | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fl NCT05004350 | Pierre Fabre Medicament | Phase 2 |
| Recruiting | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastati NCT05093907 | BeyondBio Inc. | Phase 1 / Phase 2 |
| Unknown | The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal NCT04948034 | Fudan University | Phase 2 |
| Unknown | Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer NCT05004441 | Zhou Fuxiang | Phase 2 |
| Unknown | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer NCT05023720 | Henan Cancer Hospital | — |
| Completed | RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients i NCT04920422 | Bayer | — |
| Completed | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 NCT04826003 | Hoffmann-La Roche | Phase 1 |
| Completed | Immunotherapy for Third Line Metastatic Colorectal Cancer NCT04444622 | Mirror Biologics, Inc. | Phase 2 |
| Completed | A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece NCT04965870 | Hellenic Study Group of Psychoneuroimmunology in Cancer | — |
| Terminated | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care NCT04854434 | Karyopharm Therapeutics Inc | Phase 2 |
| Active Not Recruiting | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS NCT04793958 | Mirati Therapeutics Inc. | Phase 3 |
| Unknown | Centralized Tumour Board and Secondary Intervention Rate in mCRC NCT04852250 | Ludwig-Maximilians - University of Munich | — |
| Active Not Recruiting | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With NCT04854668 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in NCT04660812 | Arcus Biosciences, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or B NCT04776655 | Azienda USL Reggio Emilia - IRCCS | Phase 3 |
| Not Yet Recruiting | Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a NCT04831528 | Fudan University | — |
| Recruiting | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Ch NCT04547166 | Shanghai Henlius Biotech | Phase 2 / Phase 3 |
| Completed | Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet NCT04898842 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) NCT06749015 | Fudan University | — |
| Unknown | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients NCT04753203 | Korean Cancer Study Group | Phase 1 / Phase 2 |
| Unknown | Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer NCT04194359 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Unknown | EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol NCT04656782 | Ludwig-Maximilians - University of Munich | — |
| Completed | Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study NCT06202417 | Fudan University | — |
| Recruiting | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorecta NCT04689347 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 1 / Phase 2 |
| Completed | Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment NCT04835142 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF NCT04466254 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Terminated | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer NCT04450836 | UNICANCER | Phase 2 |
| Active Not Recruiting | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC NCT04587128 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atez NCT04659382 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Terminated | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer NCT04108481 | University of Iowa | Phase 1 |
| Withdrawn | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer NCT04430985 | Dorte Nielsen | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer NCT04479436 | Daiichi Sankyo | Phase 2 |
| Unknown | lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Pati NCT04735900 | University Hospital, Antwerp | N/A |
| Withdrawn | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in P NCT03982173 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyr NCT04456699 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer NCT04322539 | Hutchison Medipharma Limited | Phase 3 |
| Terminated | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) NCT04166383 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chi NCT05110118 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Completed | Metastatic Colorectal Cancer. Real-World Data Analysis. NCT04757311 | Istanbul Medeniyet University | — |
| Unknown | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis El NCT04475159 | Prof. Aviram Nissan | Phase 2 |
| Completed | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) NCT04495621 | Menarini Group | Phase 1 / Phase 2 |
| Unknown | Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an NCT03940131 | King Abdullah Medical City | Phase 2 |
| Active Not Recruiting | LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy NCT04166604 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Unknown | A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) W NCT04247256 | Scandion Oncology A/S | Phase 1 / Phase 2 |
| Unknown | Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer NCT04397601 | National Cancer Institute, Naples | — |
| Completed | A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic NCT04317599 | Pierre Fabre Medicament | — |
| Completed | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patient NCT04513951 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Unknown | Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate NCT04126655 | Vastra Gotaland Region | Phase 1 / Phase 2 |
| Completed | Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC NCT04224415 | Yuhong Li | Phase 2 |
| Unknown | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoro NCT04188145 | Centre Hospitalier Universitaire Dijon | Phase 3 |
| Unknown | QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety NCT04233151 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer NCT06221423 | Fudan University | — |
| Unknown | mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy NCT05362617 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Terminated | A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) NCT04073615 | Elevar Therapeutics | Phase 1 |
| Unknown | Early Detection of Relapses in Stage IV Colorectal Cancer Patients NCT04232891 | Fondazione del Piemonte per l'Oncologia | — |
| Terminated | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC NCT03791398 | Brown University | Phase 1 / Phase 2 |
| Unknown | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC NCT04097444 | Chugai Pharmaceutical | Phase 2 |
| Active Not Recruiting | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Pa NCT04008030 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer NCT04046445 | Amal Therapeutics | Phase 1 |
| Unknown | Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer NCT04008511 | China Medical University, China | Phase 1 / Phase 2 |
| Completed | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Can NCT03829410 | Cardiff Oncology | Phase 1 / Phase 2 |
| Active Not Recruiting | QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. NCT03828227 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 3 |
| Terminated | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma NCT03785210 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patien NCT03626922 | NSABP Foundation Inc | Phase 1 |
| Completed | Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Ca NCT03828799 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 1 / Phase 2 |
| Unknown | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer NCT03977090 | Genor Biopharma Co., Ltd. | Phase 1 |
| Withdrawn | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. NCT03688230 | SFJ Pharmaceuticals X, LTD. | Phase 2 |
| Active Not Recruiting | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer NCT03867799 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cance NCT03832621 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Active Not Recruiting | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate fo NCT03869892 | Institut de Recherches Internationales Servier | Phase 3 |
| Active Not Recruiting | Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective NCT03935763 | Servier Affaires Médicales | — |
| Unknown | Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometa NCT03927898 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic NCT03892096 | Cadex Genomics | — |
| Unknown | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorec NCT03880877 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 2 |
| Completed | Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients NCT03829852 | Taipei Veterans General Hospital, Taiwan | — |
| Withdrawn | Sym004 Versus TAS-102 in Patients With mCRC NCT03717038 | Symphogen A/S | Phase 3 |
| Withdrawn | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers NCT03323424 | Institut de Cancérologie de la Loire | Phase 2 |
| Unknown | Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer NCT03142282 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Unknown | The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer NCT04230018 | Sun Yat-sen University | — |
| Completed | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer NCT03724851 | MedPacto, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer NCT03307603 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Unknown | Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer NCT03912857 | Sun Yat-sen University | Phase 2 |
| Completed | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cance NCT03721653 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Terminated | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC NCT03549338 | Symphogen A/S | Phase 2 |
| Terminated | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer NCT03645876 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer NCT03712943 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer NCT03668431 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer NCT03182894 | James J Lee | Phase 1 / Phase 2 |
| Completed | EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options NCT03602885 | Dana-Farber Cancer Institute | N/A |
| Completed | Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer NCT04561336 | University of Campania Luigi Vanvitelli | Phase 2 |
| Terminated | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659 | Georgetown University | Phase 1 / Phase 2 |
| Completed | Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). NCT03564938 | Bayer | Phase 4 |
| Active Not Recruiting | Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribo NCT03908788 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Terminated | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metasta NCT03547999 | Patrick Boland | Phase 2 |
| Completed | Trifluridin/tipirACil in MeTastatIc Colorectal Cancer NCT03665506 | Servier | — |
| Unknown | EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer NCT03542799 | Shenzhen Second People's Hospital | Phase 1 |
| Unknown | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Meta NCT03457896 | NSABP Foundation Inc | Phase 2 |
| Completed | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen fo NCT04247984 | Chinese Academy of Medical Sciences | Phase 2 |
| Withdrawn | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer NCT03340558 | Niharika Mettu | Phase 2 |
| Completed | FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Flu NCT03584711 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer NCT03186326 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer NCT03435107 | Asan Medical Center | Phase 2 |
| Completed | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy NCT03454620 | Green Cross Corporation | Phase 1 / Phase 2 |
| Completed | Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC NCT03274804 | University Hospital Heidelberg | Phase 1 |
| Completed | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer Wi NCT03256344 | Amgen | Phase 1 |
| Completed | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With NCT03374254 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC NCT03405272 | Sinocelltech Ltd. | Phase 2 |
| Unknown | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial NCT03426371 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Phase 3 |
| Completed | Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer NCT03485027 | Fudan University | Phase 2 |
| Unknown | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer NCT03391934 | Cinnagen | Phase 3 |
| Completed | Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal C NCT05316818 | Kasr El Aini Hospital | Phase 2 |
| Withdrawn | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer NCT03380689 | Fujian Cancer Hospital | Phase 1 |
| Completed | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal NCT03206151 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 3 |
| Withdrawn | AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer NCT01741038 | Mirror Biologics, Inc. | Phase 2 / Phase 3 |
| Completed | Mix Vaccine for Metastatic Colorectal Cancer NCT03357276 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Unknown | A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer NCT03356158 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Completed | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment Wi NCT03279289 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Completed | Immunophenotyping of Metastases From Colorectal Cancer NCT03604926 | Istituto Oncologico Veneto IRCCS | — |
| Unknown | RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) NCT03259009 | Association des Gastroentérologues Oncologues | — |
| Terminated | PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colo NCT03176264 | Novartis Pharmaceuticals | Phase 1 |
| Completed | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER P NCT03231722 | Gruppo Oncologico del Nord-Ovest | Phase 3 |
| Completed | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Meta NCT03263429 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Terminated | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels NCT03117972 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Withdrawn | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC NCT03222089 | Fujian Cancer Hospital | Phase 2 |
| Completed | Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal NCT03174405 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer NCT04393116 | Cankado GmbH | — |
| Completed | To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients NCT02249650 | Taiwan Sunpan Biotechnology Development Co., Ltd. | Phase 1 |
| Unknown | Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) NCT03146338 | Weprom | N/A |
| Terminated | The CHOICE Registry NCT03148093 | Taiho Oncology, Inc. | — |
| Completed | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic NCT03081494 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Circulating Tumor Cells in mCRC for Liver Resection NCT03295591 | The University of Hong Kong | — |
| Completed | Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer NCT02981524 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer NCT03150706 | Asan Medical Center | Phase 2 |
| Completed | Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies NCT03291379 | Boston Scientific Corporation | EARLY_Phase 1 |
| Unknown | Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients NCT03210064 | Hui ting Xu，MD | Phase 2 |
| Unknown | Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer NCT03132025 | Yanqiao Zhang | Phase 2 |
| Completed | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients W NCT03122509 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer NCT03168139 | TME Pharma AG | Phase 1 / Phase 2 |
| Unknown | The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer NCT03220984 | Gangnam Severance Hospital | Phase 2 |
| Completed | Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Sta NCT03274882 | Institut de Recherches Internationales Servier | Phase 2 |
| Completed | Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOL NCT03043950 | iOMEDICO AG | — |
| Completed | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer NCT03031691 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Donafenib for Previously Treated Metastatic Colorectal Cancer NCT02870582 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Terminated | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer NCT03035253 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer NCT03008499 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Unknown | Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer NCT03017807 | Sichuan Kelun Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer NCT02980510 | UNICANCER | Phase 2 |
| Withdrawn | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients NCT02965417 | Symphogen A/S | Phase 2 |
| Unknown | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC NCT04034459 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Completed | Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Color NCT02970916 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Completed | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal NCT03306394 | Institut de Recherches Internationales Servier | Phase 3 |